Clinical Trial Update: A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study [Phase 2]

View source ↗

Summary

Phase 2 safety and exploratory skin lesion measurement study of TR-701 FA completed; results posted in 2015 for major cutaneous abscess and cellulitis-related c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cellulitis
• Erysipelas
• Major Cutaneous Abscess

Drugs mentioned

• TR-701 FA

Snippet

Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Major Cutaneous Abscess, Cellulitis | Phase 2 | Status: COMPLETED | Results posted: 2015-03-12